Editas Medicine (EDIT) Tops Q2 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. DASH
9. MA
10. FND

Go back to Editas Medicine (EDIT) Tops Q2 EPS by 3c

Editas Medicine Announces Second Quarter 2022 Results and Business Updates

August 3, 2022 6:29 AM EDT

Appointed Baisong Mei, M.D., Ph.D., Chief Medical Officer, strengthening senior leadership team

Achieved successful engraftment of first patient treated with EDIT-301 for sickle cell disease; first clinical use of Editas-engineered AsCas12a enzyme

FDA removed partial clinical hold for RUBY trial of EDIT-301

Continued screening and enrolling new adult and pediatric patients for EDIT-101 Phase 1/2 BRILLIANCE study for LCA10, with clinical data update expected 2H 2022

On track to initiate IND-enabling studies of EDIT-103 for RHO-adRP by year-end; pre-IND FDA meeting feedback... More